Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COSTAR Lung
jRCT2041230056Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Aug 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Cobolimab + dostarlimab + docetaxel, Dostarlimab + docetaxel and Docetaxel alone (3 arms). Started Aug 2023; status: active, not recruiting.
02
Drugs
cobolimabdostarlimabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2041230056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230056.